热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Brilliant Violet 605™ anti-mouse CD25 Antibo
产品名称：
Brilliant Violet 605™ anti-mouse CD25 Antibo
产品类别：
抗体
产品编号：
102035
产品应用：
102035
[价格]
规格 价格 库存
125µL ￥ 3164 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-2-dependent cytolytic mouse T-cell clone B6.1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.3 ?g per million cells in 100 ?l volume. For immunofluorescent staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605? excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, in vitro blocking of IL-2 binding to low- and high-affinity receptors1-4, growth inhibition of IL-2-dependent T-cell lines1-4, in vivo depletion of CD25+CD4+ Treg cells5-8,10, and immunohistochemical staining of acetone-fixed frozen sections2. PC61 antibody recognizes a different epitope than 3C7 antibody (Cat. No. 101902).?For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 102040) with endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered.?

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. Lowenthal JW, et al. 1985. Nature 315:669. (IP, Block)
  2. Ceredig R, et al. 1985. Nature 314:98. (IP, IHC, Block)
  3. Lowenthal JW, et al. 1985. J. Immunol. 135:3988. (Block)
  4. Moreau JL, et al. 1987. Eur. J. Immunol. 17:929. (Block)
  5. Takahashi T, et al. 2000. J. Exp. Med. 192:303. (Deplete)
  6. Onizuka S, et al. 1999. Cancer Res. 59:3128. (Deplete)
  7. Lei TC, et al. 2005. Blood 105:4865. (Deplete)
  8. Pasare C, et al. 2004. Immunity 21:733. (Deplete)
  9. León-Ponte M, et al. 2007. Blood 109:3139.
  10. Cao OW, et al. 2007. Blood doi:10.1182/blood-2007-02-073304. (Deplete)
  11. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719.
  12. Liu F, et al. 2011. Arch Toxicol. 85:1383. PubMed
  13. Anguela XM, et al. 2013. Diabetes. 62:551. PubMed
Product Citations
  1. Oetjen LK et al. 2017. Cell. 171(1):217-228 . PubMed
  2. Schneider C, et al. 2018. Cell. 174:271. PubMed
  3. Angiari S, et al. 2020. Cell Metab. 31:391. PubMed
  4. Stathopoulou C, et al. 2020. Immunity. 49(2):247-263.e7.. PubMed
  5. Chen J, et al. 2021. Sci Adv. 7:. PubMed
  6. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  7. Ogbechi J, et al. 2022. Front Immunol. 13:1001956. PubMed
  8. Amir M, et al. 2018. Cell Rep. 25:3733. PubMed
  9. Paprckova D, et al. 2022. Front Immunol. 13:1009198. PubMed
  10. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  11. Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed
  12. Li Y, et al. 2020. Nat Commun. 11:2781. PubMed
  13. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  14. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  15. Singh K, et al. 2015. Sci Rep. 14:7767. PubMed
  16. Amor C, et al. 2020. Nature. 583:127. PubMed
  17. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  18. Ramos CV, et al. 2020. Cell Reports. 32(3):107910. PubMed
  19. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  20. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  21. Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed
  22. Henrich IC, et al. 2021. Cancer Res. 81:2171. PubMed
  23. Sadik A, et al. 2020. Cell. 1252:182. PubMed
  24. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  25. Hu Z, et al. 2020. PLoS One. 15:e0228339. PubMed
  26. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  27. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  28. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  29. Maulhardt HA, et al. 2020. Invest New Drugs. 1618:38. PubMed
  30. Iwanami N, et al. 2020. iScience. 23:101260. PubMed
  31. Lerbs T, et al. 2020. JCI Insight. 5:00. PubMed
  32. Dammeijer F, et al. 2020. Cancer Cell. 38(5):685-700.e8. PubMed
  33. Cobbold SP, et al. 2018. Front Immunol. 9:1381. PubMed
  34. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
RRID
AB_11126977 (BioLegend Cat. No. 102035) AB_2563059 (BioLegend Cat. No. 102036)

Antigen Details

Structure
Forms high affinity IL-2R with IL-2Rβ (CD122) and IL-2Rγ (CD132), 55 kD
Distribution

Activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells

Function
IL-2 receptor
Ligand/Receptor
IL-2
Cell Type
B cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, Cytokine/Chemokine Receptors
Antigen References
  1. Taniguchi T, et al. 1993. Cell 73:5-8.
  2. Waldmann TA. 1991. J?Biol?Chem. 266:2681-4.
  3. Read S, et al. 2000. J Exp?Med. 192:295-302.
  4. Lowenthal JW, et al. 1985. J?Immunol. 135:3988-94.
Gene ID
16184 View all products for this Gene ID
UniProt
View information about CD25 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线